Bakul I Dalal1, Areej Al Mugairi2, Steven Pi2, Soo Yeon Lee2, Nikisha S Khare2, Jason Pal2, Adam Bryant3, Alok P Vakil2, Sally Lau3, Yasser R Abou Mourad3. 1. Division of Laboratory Hematology, Vancouver General Hospital, Vancouver, BC, Canada. Electronic address: bakul.dalal@vch.ca. 2. Division of Laboratory Hematology, Vancouver General Hospital, Vancouver, BC, Canada. 3. Leukemia/Bone Marrow Transplant Program of British Columbia, BC Cancer Agency and University of British Columbia, Vancouver, BC, Canada.
Abstract
BACKGROUND: The standard-risk (SR) subgroup of acute lymphoblastic leukemia in adults (aALL) is a heterogeneous category, with a 20% to 40% relapse rate and a wide range of relapse-free survival (RFS) and overall survival (OS). There is a need to identify at the outset those patients with SR-aALL who are likely to have shorter RFS and OS, so they can be treated more aggressively. PATIENTS AND METHODS: Flow cytometric data of 81 patients with SR-aALL treated with a standardized protocol were retrospectively analyzed. Thirty-two patients (40%) relapsed; the median RFS and OS were 12.5 months (range, 1-136 months) and 30 months (range, 3-235 months), respectively. Twenty-six patients survived ≥ 48 months. RESULTS: Expression of myeloid antigen CD13, using the conventional ≥ 20% threshold and a lower ≥ 5% threshold, was seen in 17 (29%) of 59 and 29 (49%) of 59 patients, respectively, whereas dual expression of CD13 and CD33 was seen in 8 patients. CD13 positivity at ≥ 20% and ≥ 5% threshold was associated with a shorter RFS (P = .0158 and P < .0001, respectively) and OS (P = .0072 and P < .0001, respectively). Dual expression of CD13 (at ≥ 5% or ≥ 20% threshold) and CD33 was associated with inferior OS (P = .0038 and P = .0032, respectively) and RFS (P = .0705 and P = .2516, respectively). For ≥ 20% and ≥ 5% threshold of positivity, 16 of 42 and 28 of 42 who survived < 48 months were positive, compared with 1 of 17 and 1 of 17 who survived ≥ 48 months (P = .0133 and P < .0001, respectively). CONCLUSION: Aberrant expression of CD13 in ≥ 5% of blasts of patients with SR-aALL is an adverse prognostic factor, delineating a subgroup of patients with SR-aALL that should be considered for more aggressive treatment.
BACKGROUND: The standard-risk (SR) subgroup of acute lymphoblastic leukemia in adults (aALL) is a heterogeneous category, with a 20% to 40% relapse rate and a wide range of relapse-free survival (RFS) and overall survival (OS). There is a need to identify at the outset those patients with SR-aALL who are likely to have shorter RFS and OS, so they can be treated more aggressively. PATIENTS AND METHODS: Flow cytometric data of 81 patients with SR-aALL treated with a standardized protocol were retrospectively analyzed. Thirty-two patients (40%) relapsed; the median RFS and OS were 12.5 months (range, 1-136 months) and 30 months (range, 3-235 months), respectively. Twenty-six patients survived ≥ 48 months. RESULTS: Expression of myeloid antigen CD13, using the conventional ≥ 20% threshold and a lower ≥ 5% threshold, was seen in 17 (29%) of 59 and 29 (49%) of 59 patients, respectively, whereas dual expression of CD13 and CD33 was seen in 8 patients. CD13 positivity at ≥ 20% and ≥ 5% threshold was associated with a shorter RFS (P = .0158 and P < .0001, respectively) and OS (P = .0072 and P < .0001, respectively). Dual expression of CD13 (at ≥ 5% or ≥ 20% threshold) and CD33 was associated with inferior OS (P = .0038 and P = .0032, respectively) and RFS (P = .0705 and P = .2516, respectively). For ≥ 20% and ≥ 5% threshold of positivity, 16 of 42 and 28 of 42 who survived < 48 months were positive, compared with 1 of 17 and 1 of 17 who survived ≥ 48 months (P = .0133 and P < .0001, respectively). CONCLUSION: Aberrant expression of CD13 in ≥ 5% of blasts of patients with SR-aALL is an adverse prognostic factor, delineating a subgroup of patients with SR-aALL that should be considered for more aggressive treatment.
Authors: Benjamin D Moore; Ramon U Jin; Luciana Osaki; Judith Romero-Gallo; Jennifer Noto; Richard M Peek; Jason C Mills Journal: Am J Physiol Gastrointest Liver Physiol Date: 2015-10-29 Impact factor: 4.052
Authors: Juho J Miettinen; Romika Kumari; Gunnhildur Asta Traustadottir; Maiju-Emilia Huppunen; Philipp Sergeev; Muntasir M Majumder; Alexander Schepsky; Thorarinn Gudjonsson; Juha Lievonen; Despina Bazou; Paul Dowling; Peter O Gorman; Ana Slipicevic; Pekka Anttila; Raija Silvennoinen; Nina N Nupponen; Fredrik Lehmann; Caroline A Heckman Journal: Cancers (Basel) Date: 2021-03-26 Impact factor: 6.639
Authors: Rhys J P Skelton; Bevin Brady; Suhail Khoja; Debashis Sahoo; James Engel; Deevina Arasaratnam; Kholoud K Saleh; Oscar J Abilez; Peng Zhao; Edouard G Stanley; Andrew G Elefanty; Murray Kwon; David A Elliott; Reza Ardehali Journal: Stem Cell Reports Date: 2016-01-12 Impact factor: 7.765
Authors: Sebastian P Haen; Benjamin J Schmiedel; Kathrin Rothfelder; Bastian J Schmied; Truong-Minh Dang; Nora Mirza; Robert Möhle; Lothar Kanz; Wichard Vogel; Helmut R Salih Journal: Oncotarget Date: 2016-03-15